Seres Therapeutics (NASDAQ:MCRB) Stock Rating Upgraded by HC Wainwright

Seres Therapeutics (NASDAQ:MCRB) was upgraded by HC Wainwright to a “strong-buy” rating in a report issued on Tuesday,Zacks.com reports. HC Wainwright also issued estimates for Seres Therapeutics’ Q2 2026 earnings at ($2.07) EPS, Q3 2026 earnings at ($0.90) EPS, Q4 2026 earnings at ($0.93) EPS, FY2026 earnings at ($5.84) EPS, FY2027 earnings at ($2.87) EPS and FY2028 earnings at ($3.03) EPS.

Several other analysts have also issued reports on MCRB. Canaccord Genuity Group reiterated a “buy” rating and set a $22.00 price target on shares of Seres Therapeutics in a research report on Friday, March 13th. Wall Street Zen upgraded shares of Seres Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, June 6th. Finally, Weiss Ratings downgraded Seres Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Monday, May 18th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $17.00.

Seres Therapeutics Stock Up 6.8%

Shares of Seres Therapeutics stock opened at $7.05 on Tuesday. The company has a market capitalization of $68.24 million, a price-to-earnings ratio of -1.36 and a beta of 0.13. Seres Therapeutics has a 12-month low of $5.31 and a 12-month high of $29.98. The firm’s 50-day moving average price is $7.46 and its two-hundred day moving average price is $10.67.

Seres Therapeutics (NASDAQ:MCRB) last released its earnings results on Tuesday, May 5th. The biotechnology company reported ($2.08) EPS for the quarter, missing the consensus estimate of ($1.88) by ($0.20). The business had revenue of $0.36 million for the quarter, compared to analysts’ expectations of $0.36 million.

Institutional Investors Weigh In On Seres Therapeutics

Several hedge funds have recently added to or reduced their stakes in MCRB. Goldman Sachs Group Inc. increased its position in Seres Therapeutics by 40.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company’s stock valued at $52,000 after acquiring an additional 21,679 shares during the period. Invesco Ltd. grew its stake in shares of Seres Therapeutics by 193.2% in the first quarter. Invesco Ltd. now owns 136,572 shares of the biotechnology company’s stock worth $96,000 after purchasing an additional 89,995 shares during the last quarter. Bank of America Corp DE increased its holdings in Seres Therapeutics by 2,772.6% in the third quarter. Bank of America Corp DE now owns 5,343 shares of the biotechnology company’s stock valued at $103,000 after purchasing an additional 5,157 shares during the period. Barclays PLC increased its holdings in Seres Therapeutics by 427.8% in the fourth quarter. Barclays PLC now owns 7,432 shares of the biotechnology company’s stock valued at $111,000 after purchasing an additional 6,024 shares during the period. Finally, ExodusPoint Capital Management LP bought a new position in Seres Therapeutics during the 4th quarter worth $190,000. 59.34% of the stock is currently owned by institutional investors and hedge funds.

Seres Therapeutics Company Profile

Seres Therapeutics is a clinical‐stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.